Streetbeat News

Stock Prices

MU

Investors have shown a bearish stance on Micron Technology (NASDAQ:MU), with options trading data revealing a split sentiment of 22% bullish and 77% bearish. The options trades indicate a price target window of $70.0 to $92.5 for MU. The trading volume and open interest suggest significant activity in MU options, with a notable shift towards bearish positions. Micron Technology, a major semiconductor company, is currently trading at $86.06, with an upcoming earnings announcement in 54 days.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 5:00 pm

EAT

BMO Capital has reaffirmed its Outperform rating on Brinker International (NYSE:EAT), raising its price target from $52.00 to $55.00. Brinker's shares have risen 1.19% in the last 24 hours to $43.30. The new target suggests a potential 27.02% increase. Brinker operates Chili's and Maggiano's Little Italy, with Chili's being the major revenue contributor.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 5:00 pm

TMO

RBC Capital has reaffirmed its Outperform rating for Thermo Fisher Scientific (TMO) and increased its price target from $592.00 to $642.00, indicating a potential 18.69% upside from the current share price of $540.89. Thermo Fisher Scientific is a leading provider of scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents, operating across four segments.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 5:00 pm

ENPH

Roth MKM has maintained its Buy rating for Enphase Energy (NASDAQ:ENPH) but lowered its price target from $150.00 to $140.00. Despite this, shares of Enphase Energy have risen 2.41% in the last 24 hours to $106.64. The new price target suggests a potential 31.28% increase from the current share price. Enphase Energy is a global energy technology company focusing on solar generation, storage, and communication solutions, with the majority of its revenue coming from the United States.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 5:00 pm

SCCO

Southern Copper (NYSE:SCCO) has significantly outperformed the market with an average annual return of 19.59% over the past 5 years, turning a $1000 investment into $2,457.95 today. The company's market capitalization stands at $64.30 billion.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 5:00 pm

PWR

Quanta Services (NYSE:PWR) has delivered an average annual return of 16.12% over the past 15 years, outperforming the market by 3.97% annually. A $100 investment in PWR 15 years ago would now be worth $947.38. The company currently has a market capitalization of $28.81 billion.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 5:00 pm

IONS

JP Morgan has maintained its Neutral rating for Ionis Pharmaceuticals (NASDAQ:IONS) but raised its price target from $52.00 to $55.00. Ionis Pharmaceuticals, a leader in antisense technology for drug development, has seen its shares increase by 0.62% in the last 24 hours to $51.71. The new price target represents a 6.36% potential upside. Ionis has successfully brought several drugs to market, including treatments for spinal muscular atrophy and ALS, through partnerships and its subsidiaries.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 5:00 pm

PTC

Rosenblatt has reaffirmed its Buy rating on PTC (NASDAQ:PTC), increasing the price target from $166.00 to $195.00. Despite a recent 2.02% decline in PTC's stock price to $177.00, the new target suggests a potential 10.17% upside. PTC specializes in high-end CAD and PLM software, along with IoT and AR solutions, primarily serving North America and Europe.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 5:00 pm

KPRX

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) shares surged after announcing a private placement of up to $45 million and an exclusive license and development agreement with Théa Open Innovation SAS. The deal includes an upfront payment of $16 million to Kiora, potential milestone payments of up to $285 million, and tiered royalties on net sales. Additionally, Kiora will issue 15,800,000 shares and warrants to institutional investors for approximately $15 million, with potential future proceeds of $30 million from warrant exercises. KPRX's stock is currently trading above its 200-day moving average, indicating a bullish signal.

Portfolio Pulse from Erica Kollmann

February 01, 2024 | 4:57 pm

KPRX

Kiora Pharmaceuticals' stock is trading higher following the announcement of a private placement worth up to approximately $45 million.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 4:56 pm